76. 下垂体性ゴナドトロピン分泌亢進症 Pituitary gonadotropin secretion hyperthyroidism Clinical trials / Disease details


臨床試験数 : 28 薬物数 : 46 - (DrugBank : 14) / 標的遺伝子数 : 6 - 標的パスウェイ数 : 19

  
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03963752
(ClinicalTrials.gov)
August 15, 201922/5/2019Clinical Trial of Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western MedicineEvidence-based Medical Research on the Treatment of Children's Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western MedicineIdiopathic Precocious PubertyDrug: Ziyinxiehuo Granules Herbs;Drug: Megestrol Acetate Tablet;Drug: Leuprorelin Acetate 3.75mg InjectionChildren's Hospital of Fudan UniversityNULLRecruiting5 Years8 YearsFemale164Phase 4China
2NCT03316482
(ClinicalTrials.gov)
June 11, 201512/10/2017Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious PubertyA Multicenter, Open, Prospective Study to Evaluate the Safety and Efficacy of Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious PubertyCentral Precocious PubertyDrug: Leuplin DPS 11.25mgJin Soon HwangNULLCompleted4 Years9 YearsAll58Phase 4Korea, Republic of
3EUCTR2014-004495-36-Outside-EU/EEA
(EUCTR)
28/11/2014A study of Lupron Depot Lupron Depot in treatment of central premature pubertyStudy of Lupron Depot in the Treatment of Central Precocious Puberty Central Precocious Puberty
MedDRA version: 17.1;Level: LLT;Classification code 10073186;Term: Central precocious puberty;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Trade Name: trade name depends on the source of the product
INN or Proposed INN: LEUPRORELIN ACETATE
Trade Name: trade name depends on the source of the product
INN or Proposed INN: LEUPRORELIN ACETATE
Abbvie previously known as AbbottNULLNAFemale: yes
Male: yes
55United States
4EUCTR2014-004494-16-Outside-EU/EEA
(EUCTR)
03/12/2014A clinical trial to determine safety and efficacy of Leuprolide Acetate 11.25mg and 30mg in children with central premature pubertyA 36 Month, Multi-Center, Open-Label Extension Study to Evaluate theSafety of Leuprolide Acetate 11.25 mg and 30 mg Formulations inChildren with Central Precocious Puberty Central Precocious Puberty
MedDRA version: 17.1;Level: LLT;Classification code 10073186;Term: Central precocious puberty;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Trade Name: trade name depends on the source of the product
INN or Proposed INN: LEUPRORELIN ACETATE
Trade Name: trade name depends on the source of the product
INN or Proposed INN: LEUPRORELIN ACETATE
Abbvie previously known as AbbottNULLNAFemale: yes
Male: yes
72United States;Puerto Rico
5EUCTR2014-004493-42-Outside-EU/EEA
(EUCTR)
03/12/2014A clinical trial to determine safety and efficacy of Leuprolide Acetate 11.25mg and 30mg in children with central premature pubertyA Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate theEfficacy and Safety of Leuprolide Acetate 11.25 and 30 mg Formulationsin Children with Central Precocious Puberty Central Precocious Puberty
MedDRA version: 17.1;Level: LLT;Classification code 10073186;Term: Central precocious puberty;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Trade Name: trade name depends on the source of the product
Product Name: Leuprolide acetate depot
INN or Proposed INN: LEUPRORELIN ACETATE
Trade Name: trade name depends on the source of the product
INN or Proposed INN: LEUPRORELIN ACETATE
Abbvie previously known as AbbottNULLNAFemale: yes
Male: yes
80Phase 3United States;Puerto Rico